Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A stabilized oral formulation of the BPC-157 pentadecapeptide sequence designed for gastrointestinal applications. Unlike standard BPC-157 which is typically injected, this formulation uses stabilization techniques to survive gastric acid degradation. Primarily studied for gut healing, ulcer protection, and inflammatory bowel conditions.
A synthetic 15-amino acid peptide derived from a protective protein found in human gastric juice. One of the most widely researched peptides for tissue repair and recovery.
Same core mechanism as BPC-157 — upregulates growth factor expression (VEGF, EGF), promotes angiogenesis, and modulates the nitric oxide system. The oral formulation targets the GI tract directly, providing local healing effects on the gastric and intestinal mucosa before systemic absorption.
BPC-157 promotes angiogenesis (new blood vessel formation), upregulates growth factor expression, and modulates nitric oxide synthesis. It appears to accelerate healing of tendons, ligaments, muscles, and the GI tract through multiple pathways including the FAK-paxillin pathway.
- Gut healing and repair
- Gastric ulcer protection
- Inflammatory bowel support
- Leaky gut syndrome (investigational)
- NSAID-induced GI damage protection
- Tendon and ligament repair
- Gut healing and GI protection
- Muscle injury recovery
- Joint health
- Post-surgical recovery
- Limited human clinical data
- GI discomfort possible
- Uncertain bioavailability compared to injectable
- Quality varies significantly between suppliers
- Not FDA-approved for any indication
- Limited human clinical trial data
- Most research is animal-based
- Potential interactions with blood pressure medications
- Injection site reactions
- Long-term safety profile unknown
Shares regulatory status with BPC-157. Removed from Category 2 on April 22, 2026. Awaiting PCAC review at the July 23, 2026 meeting. The oral formulation is not separately categorized by the FDA — it falls under the same BPC-157 regulatory umbrella.
PCAC: 2026-07-23
On April 15, 2026, the FDA announced BPC-157 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. It is now scheduled for formal PCAC (Pharmacy Compounding Advisory Committee) review on July 23, 2026, to determine whether it should be added to the 503A bulk drug substances list. Removal from Category 2 does not authorize compounding — pharmacies should exercise caution until PCAC issues its recommendation. Previously reclassified to Category 1 in February 2026, a step that is now superseded by this more formal process.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.